Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 13(1): 2084, 2023 02 06.
Article in English | MEDLINE | ID: mdl-36747073

ABSTRACT

The aims of this study were to perform pre-surgery miRNA profiling of patients who develop Vasoplegic syndrome (VS) after coronary artery bypass grafting (CABG) and identify those miRNAs that could be used as VS prognostic tools and biomarkers. The levels of 754 microRNAs (miRNAs) were measured in whole blood samples from a cohort of patients collected right before the coronary artery bypass grafting (CABG) surgery. We compared the miRNA levels of those who developed VS (VASO group) with those who did not (NONVASO group) after surgery. Six miRNAs (hsa-miR-548c-3p, -199b-5p, -383-5p -571 -183-3p, -30d-5p) were increased and two (hsa-1236-3p, and hsa-miR770-5p) were decreased in blood of VASO compared to NONVASO groups. Receiver Operating Characteristic (ROC) curve analysis revealed that a combination of the miRNAs, hsa-miR-30d-5p and hsa-miR-770-5p can be used as VS predictors (AUC = 0.9615, p < 0.0001). The computational and functional analyses were performed to gain insights into the potential role of these dysregulated miRNAs in VS and have identified the "Apelin Liver Signaling Pathway" as the canonical pathway containing the most target genes regulated by these miRNAs. The expression of the combined miRNAs hsa-miR-30d and hsa-miR-770-5p allowed the ability to distinguish between patients who could and could not develop VS, representing a potential predictive biomarker of VS.


Subject(s)
MicroRNAs , Vasoplegia , Humans , Vasoplegia/genetics , MicroRNAs/metabolism , Biomarkers , Prognosis , Signal Transduction , Gene Expression Profiling
2.
J Cardiovasc Pharmacol Ther ; 21(1): 100-13, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26025460

ABSTRACT

We investigated the effect of erythropoietin (EPO) posttreatment on survival time and vascular functions in a mouse model of sepsis. Sepsis was induced by cecal ligation and puncture. After 20 ± 2 hours of sepsis, thoracic aorta was isolated for assessing its reactivity to norepinephrine (NE) and acetylcholine (ACh). We also measured the tissue nitric oxide (NO) level, inducible nitric oxide synthase (iNOS), endothelial nitric oxide synthase (eNOS), G protein-coupled receptor kinase 2 (GRK2), and α1D adrenoceptor messenger RNA (mRNA)/protein expression. In septic mice, EPO moderately improved the survival time from 19.68 ± 0.75 to 34.7 ± 3.2 hours. Sepsis significantly decreased the aortic contractile response to NE along with reduced α1D mRNA and protein expression. Erythropoietin significantly preserved the α1D receptor expression and restored NE-induced contractions to control levels in septic mice. Further, it attenuated the aortic α1D receptor desensitization in sepsis which was evident from reduced GRK2 mRNA expression. Accordingly, a selective GRK2 inhibitor markedly restored the contractile responses to NE in sepsis. Erythropoietin treatment attenuated iNOS mRNA expression and iNOS-induced overproduction of NO, but improved endothelium-dependent relaxation to ACh associated with increased eNOS mRNA expression. In conclusion, EPO seems to reverse sepsis-induced vasoplegia to NE through the preservation of α1D adrenoceptor mRNA/protein expression, inhibition of GRK2-mediated desensitization, and attenuation of NO overproduction in the mouse aorta.


Subject(s)
Adrenergic alpha-Agonists/pharmacology , Aorta, Thoracic/drug effects , Erythropoietin/pharmacology , G-Protein-Coupled Receptor Kinase 2/metabolism , Norepinephrine/pharmacology , RNA, Messenger/metabolism , Receptors, Adrenergic, alpha-1/drug effects , Sepsis/drug therapy , Vasoconstrictor Agents/pharmacology , Vasoplegia/prevention & control , Animals , Aorta, Thoracic/enzymology , Aorta, Thoracic/physiopathology , Cecum/microbiology , Cecum/surgery , Disease Models, Animal , Dose-Response Relationship, Drug , G-Protein-Coupled Receptor Kinase 2/antagonists & inhibitors , G-Protein-Coupled Receptor Kinase 2/genetics , Ligation , Male , Mice , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/genetics , Nitric Oxide Synthase Type II/metabolism , Nitric Oxide Synthase Type III/metabolism , Protein Kinase Inhibitors/pharmacology , Punctures , RNA, Messenger/genetics , Receptors, Adrenergic, alpha-1/genetics , Receptors, Adrenergic, alpha-1/metabolism , Sepsis/complications , Sepsis/enzymology , Sepsis/microbiology , Sepsis/physiopathology , Signal Transduction/drug effects , Time Factors , Vasoconstriction/drug effects , Vasodilation/drug effects , Vasodilator Agents/pharmacology , Vasoplegia/enzymology , Vasoplegia/etiology , Vasoplegia/genetics , Vasoplegia/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...